SQ Innovation Closes Series B to Commercialize FDA-Approved Heart Failure Drug

SQ Innovation AG, a life-science company, has successfully closed a Series B financing round to accelerate the U.S. commercial launch of its newly FDA-approved heart failure treatment, Lasix® ONYU. The financing closes just after the company received approval from the U.S. Food and Drug Administration on October 7, 2025.

The transaction marks a critical inflection point for the company, providing the necessary capital to enter the substantial U.S. market. Lasix® ONYU is a drug-device combination designed to treat edema in heart failure patients at home, directly addressing the significant costs associated with hospitalization, a primary concern for payors and health systems. Heart failure is a leading cause of hospital admissions for Americans over 65, affecting a market of approximately 6.7 million patients.

With regulatory approval secured and financing in place, SQ Innovation plans a commercial launch in the fourth quarter of 2025. The financing was led by Mr. van der Poel with further participation from new and existing shareholders.

Lenz & Staehelin advised SQ Innovation on the financing. The team included Simone Ehrsam, Tino Gaberthüel, Nicolas Lehmann, Raphael Fries, and Lucas Gericke (all Corporate and M&A), as well as Peter Ling (IP).